⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995426 | 1.00 | — | — | |
| SCHEMBL9900036 | 0.74 | — | — | |
| SCHEMBL8043096 | 0.74 | — | — | |
| SCHEMBL13521647 | 0.74 | — | — | |
| SCHEMBL19234198 | 0.67 | — | — | |
| SCHEMBL1668811 | 0.67 | — | — | |
| SCHEMBL8988873 | 0.67 | — | — | |
| SCHEMBL8804736 | 0.67 | — | — | |
| SCHEMBL13652984 | 0.67 | — | — | |
| SCHEMBL1669127 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952289-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
| US-20210299113-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-09-30 | — | — | US | disclosed |
| EP-3515887-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20200261411-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-08-20 | — | — | US | disclosed |
| US-10588891-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| EP-3515887-A1 | TRPV4 ANTAGONISTS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| US-20190216774-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| CN-109952289-A | TRPV4 antagonist | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-06-28 | — | — | CN | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018055524-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-29 | — | — | WO | disclosed |